Keywords: map, tempo, migraine, drug, sees, strong, ph

MAP's Tempo migraine drug sees strong Ph II data

Article | 12 March 2007

Print This

The USA's MAP Pharmaceuticals says that its candidate migraine treatment met its primary endpoints in a Phase II clinical program ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in